Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523453 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL27886063 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL10195853 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL14659304 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL27542616 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL4716526 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL4716523 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL12414687 | 0.88 | KMT2A (0.64) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL524061 | 0.85 | KMT2A (0.61) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL8331016 | 0.85 | KMT2A (0.61) | KMT2AMAPK1HSD17B2GRM5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103827090-B | Substituted quinolines and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| CN-103827090-A | Substituted quinolines and their use as pharmaceuticals | BOEHRINGER INGELHEIM INT | 2014-05-28 | — | — | CN | disclosed |
| CN-102822172-A | Substituted naphthyridines and their use as syk kinase inhibitors | BOEHRINGER INGELHEIM INT | 2012-12-12 | — | — | CN | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | KMT2A 4357/4885MAPK1 3154/4885HSD17B2 552/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | KMT2A 4357/4885MAPK1 3154/4885HSD17B2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.